Thrombolysis vs. Thrombectomy: What’s the Difference?

Thrombolysis dissolves a blood clot with medication, while thrombectomy physically removes it with a catheter-based device. Both treatments aim to restore blood flow through a blocked vessel, but they differ in mechanism, speed, eligibility, and risk profile. In acute stroke care, the two are often used together, and understanding when each applies can clarify a confusing part of emergency medicine.

How Each Treatment Works

Thrombolysis uses a clot-dissolving drug, most commonly alteplase (also called tPA), delivered through a standard intravenous line. The drug circulates through the bloodstream and activates a natural enzyme that breaks down the fibrin mesh holding a clot together. Because it is systemic, it reaches clots wherever they are, but it also affects clotting throughout the body, which is why bleeding is its primary risk.

Thrombectomy is a minimally invasive procedure performed in a specialized suite. A catheter is threaded through an artery, usually starting from the groin, and guided up to the site of the blockage using real-time imaging. Once at the clot, the interventionalist uses one of several techniques to extract it. Stent retrievers expand inside the clot, mesh around it, and pull it out. Aspiration catheters use vacuum suction to suck the clot into the catheter. A combined approach deploys both at once: a stent retriever pins the clot while an aspiration catheter seals against its front end, and the whole system is withdrawn together.¹

The practical upshot: thrombolysis can be started quickly at almost any hospital with an emergency department, while thrombectomy requires a hospital with a neurointerventional team and an angiography suite, which limits where it can be performed.

Who Is Eligible for Each

Thrombolysis has a narrower eligibility window in several respects. The standard treatment window for intravenous tPA in stroke is up to 4.5 hours after symptom onset.² Patients on blood thinners, those with recent surgery, or people with clotting disorders are generally excluded because the drug raises the risk of uncontrolled bleeding. Recanalization rates with tPA alone have historically been reported below 50% for large vessel blockages.³

Thrombectomy has a wider treatment window and can be used in patients who cannot receive clot-dissolving drugs, including those with coagulopathy. The procedure also achieves higher recanalization rates in large vessel occlusions, with some reports reaching above 80%.³ However, thrombectomy is only appropriate when a large artery is blocked. For strokes caused by small-vessel disease or blockages in vessels too tiny for a catheter to reach, thrombolysis remains the primary option.

Time Windows and the Role of Imaging

Time is the central constraint in stroke treatment. For thrombolysis, the traditional cutoff is 4.5 hours, but imaging-guided trials have pushed that boundary. The EXTEND trial showed that patients selected by perfusion imaging could benefit from intravenous alteplase between 4.5 and 9 hours after symptom onset, including people who woke up with a stroke.⁴ The key is identifying brain tissue that is still salvageable, even if the clock has ticked past the standard cutoff.

For thrombectomy, the window extends even further. The landmark DAWN and DEFUSE-3 trials demonstrated that thrombectomy could benefit selected patients with large vessel blockages up to 24 hours after symptom onset, as long as imaging confirmed there was still a meaningful mismatch between the area at risk and the area already damaged.⁵ The DEFUSE-3 trial specifically enrolled patients 6 to 16 hours out, requiring a small initial infarct size and a favorable ratio of at-risk tissue to already-dead tissue on perfusion imaging.⁶

This shift matters practically. A patient arriving at the hospital 10 hours after their stroke began would almost certainly be ineligible for intravenous thrombolysis, but could still be a candidate for thrombectomy if their brain scan looks favorable. Advanced imaging has effectively replaced the rigid clock as the primary gatekeeper for treatment, though earlier treatment still yields better results in both approaches.

Outcomes When the Two Compete Head-to-Head

Comparing thrombectomy directly against thrombolysis is tricky because they are often used in different clinical scenarios. Thrombolysis is the go-to for most strokes; thrombectomy is reserved for the subset involving large vessel occlusions. Still, in situations where both could theoretically apply, the evidence favors thrombectomy for large blockages.

A meta-analysis of randomized trials found that mechanical thrombectomy was associated with roughly a 45% higher chance of achieving a good functional outcome at 90 days compared with standard medical care alone.⁷ Long-term data confirmed that these benefits held beyond the 90-day mark, with thrombectomy patients maintaining higher functional independence and better quality of life at extended follow-up.⁸

In basilar artery occlusion, a particularly severe type of stroke, one single-center comparison found that mechanical thrombectomy achieved complete recanalization in about 88% of cases, compared with roughly 42% for intra-arterial thrombolysis delivered directly to the clot site.⁹ A network meta-analysis similarly showed that direct thrombectomy had a significantly higher successful revascularization rate and better functional independence than tPA alone.¹⁰

Bridging Therapy, or Why Doctors Often Use Both

In practice, many patients with large vessel strokes receive thrombolysis first, as a bridge while being transferred or prepped for thrombectomy. This strategy is called “bridging therapy.” The logic is straightforward: start dissolving the clot immediately with medication, then go in with a catheter to finish the job.

Whether bridging therapy actually beats thrombectomy alone has been one of the most debated questions in stroke medicine. An earlier meta-analysis found that bridging with intravenous thrombolysis before thrombectomy led to significantly better functional independence, lower mortality at 90 days, and higher recanalization rates compared with direct thrombectomy alone, without increasing the risk of symptomatic bleeding.¹¹ However, a later systematic review of randomized clinical trials found no significant difference in functional independence between the two strategies, though bridging therapy did show slightly higher rates of successful blood-vessel reopening on follow-up imaging.¹²

A matched-control study echoed this ambiguity: patients who received thrombectomy alone had outcomes comparable to those who received both treatments, but the thrombectomy-alone group had shorter door-to-procedure times and lower rates of symptomatic intracranial hemorrhage.¹³ The picture is still evolving, but the emerging consensus is that bridging is beneficial when it does not meaningfully delay getting to the catheter, and skipping it may be reasonable at hospitals where thrombectomy can start immediately.

The Clot Itself Matters

Not all blood clots respond equally to either treatment. Clot composition varies considerably, and this affects which approach works better. Clots rich in red blood cells tend to dissolve more readily with tPA. Clots dominated by fibrin are more resistant to thrombolysis and also tend to require more retrieval passes during thrombectomy.¹⁴ Clinicians cannot always know the clot’s makeup before treatment begins, but certain imaging characteristics can offer clues. A dense, bright clot on a CT scan often suggests a red-blood-cell-rich composition, which bodes well for thrombolysis. A less visible clot may hint at higher fibrin content and a tougher fight either way.

Risk Profiles

Both treatments carry risks, but the nature of those risks differs. For thrombolysis, the headline concern is symptomatic intracranial hemorrhage. This occurs in roughly 5 to 6% of patients receiving tPA, and when it happens the consequences are severe, with high mortality and poor functional outcomes.¹⁵ Risk factors for this complication include older age, higher stroke severity at baseline, elevated blood pressure, high blood glucose, and certain pre-existing conditions like prior microbleeds on brain MRI.¹⁶

Thrombectomy’s risks are more procedural. A large registry study found that complications occurred in about 8% of thrombectomy cases. The most common was embolization to a new territory, meaning the clot or a fragment dislodged and traveled to block a previously unaffected vessel. This happened in about 5% of procedures and was associated with significantly worse outcomes, including higher mortality. Vessel perforations were rarer, occurring in under 2% of cases, but were devastating when they did occur, with about 41% of those patients dying within 90 days.¹⁷ Vessel dissections were also uncommon and did not significantly affect long-term outcomes.

Tenecteplase and the Future of Thrombolytic Drugs

Alteplase has been the standard thrombolytic drug for decades, but tenecteplase is gaining ground. Tenecteplase has practical advantages: it can be given as a single quick injection instead of the hour-long infusion alteplase requires, which simplifies emergency room logistics and may speed up care, especially during transfers.

In terms of effectiveness, the evidence has been reassuring. A large randomized trial (ORIGINAL) found that tenecteplase was noninferior to alteplase, with similar rates of functional independence at 90 days and identical rates of symptomatic intracranial hemorrhage.¹⁸ A systematic review and meta-analysis found that tenecteplase was associated with better early neurological improvement and higher vessel reopening rates compared with alteplase.¹⁹ A smaller phase 2 trial found no significant difference in penumbral salvage or bleeding rates between the two drugs.²⁰

Where tenecteplase gets especially interesting is in bridging therapy. A network meta-analysis found that low-dose tenecteplase combined with thrombectomy produced better functional outcomes than thrombectomy alone, and outperformed the traditional combination of alteplase plus thrombectomy as well.²¹ Many stroke systems around the world are now transitioning to tenecteplase as their default thrombolytic, a shift driven as much by ease of use as by clinical performance.

Getting to the Right Hospital

Because thrombectomy can only be performed at specialized comprehensive stroke centers, one of the biggest practical questions in emergency stroke care is where to take the patient. There are two models: “mothership,” in which the ambulance drives directly to the thrombectomy-capable hospital, and “drip-and-ship,” in which the patient is taken to the nearest primary stroke center for thrombolysis first and then transferred for thrombectomy if needed.

Meta-analyses have generally favored the mothership model for functional outcomes. One systematic review found that the mothership approach was associated with higher rates of functional independence at 90 days, though mortality and recanalization rates were similar between the two models.²² The advantage of mothership was tied to shorter onset-to-treatment times. A more recent meta-analysis estimated that the mothership model confers superior outcomes when the additional delay in the drip-and-ship pathway exceeds roughly 43 minutes.²³

Geography complicates this. When the comprehensive center is far away and a primary stroke center is close, drip-and-ship can actually be the better choice because it gets thrombolysis started sooner. A modeling study found that when both hospital types are more than about 90 minutes away, the drip-and-ship pathway becomes the favored strategy.²⁴ In dense urban areas with a comprehensive center nearby, mothership wins. In rural settings, drip-and-ship is usually unavoidable and may still be optimal.

Cost-Effectiveness

Thrombectomy is more expensive upfront than thrombolysis, requiring a specialized team, an angiography suite, and often pricey catheter devices. But economic analyses consistently show it pays for itself through better outcomes. One analysis based on the DAWN and DEFUSE-3 trials found that thrombectomy beyond 6 hours had an incremental cost-effectiveness ratio well below commonly used thresholds, with a probability above 99.9% of being cost-effective.²⁵ An earlier UK-based analysis estimated the cost per quality-adjusted life year gained with thrombectomy at roughly £7,000 over 20 years, far below the threshold typically used to judge value in that system.²⁶

An international cost-effectiveness study added a useful nuance for bridging therapy: combining thrombolysis with thrombectomy was cost-effective in most countries when the thrombolytic could be started within about two and a half hours of symptom onset, but the cost-effectiveness vanished once onset-to-thrombolysis time exceeded roughly three hours and 20 minutes.²⁷ This reinforces the time-sensitive nature of the decision: bridging adds value only when the thrombolytic drug can be delivered quickly.

Beyond Stroke

Thrombolysis and thrombectomy are not limited to the brain. Both are used to treat blood clots in the lungs (pulmonary embolism) and in the leg arteries and veins (peripheral vascular disease), and the tradeoffs between the two look different outside the stroke setting.

For pulmonary embolism, a multicenter study found that catheter-directed thrombolysis and mechanical thrombectomy had similar composite outcomes, though thrombectomy patients spent fewer days in intensive care.²⁸ A separate meta-analysis found that catheter-directed thrombolysis had lower in-hospital mortality than thrombectomy overall, though when the comparison was narrowed to catheter-based thrombectomy devices (as opposed to open surgical thrombectomy), the mortality difference disappeared.²⁹

In the legs, the story is somewhat clearer. For acute deep vein thrombosis, a meta-analysis found that mechanical thrombectomy had much better six-month patency rates than thrombolysis, with lower rates of major bleeding.³⁰ A study of AngioJet mechanical thrombectomy for acute lower-limb DVT found significantly higher clot clearance rates, shorter hospital stays, and greater patient satisfaction compared with catheter-directed thrombolysis.³¹ For critical limb ischemia caused by blocked arteries, mechanical thrombectomy similarly outperformed thrombolysis on one-year vessel patency, with shorter hospital stays and fewer major bleeding events.³² The peripheral vascular data, while still growing, suggest that thrombectomy’s advantages in speed and vessel patency hold outside the brain as well, though each clinical scenario has its own considerations around anatomy, clot burden, and patient health.